| Industry Symposia
|
|
|
|
Thanks to WCN’22 sponsors for hosting
today’s industry symposia:
|
Baxter Malaysia:
What Has COVID Taught Us & How Does the
Future Look Like?
|
|
Kyowa Kirin:
Dialysis Treatment Trends from a Global
Perspective
|
|
Baxter Malaysia:
Rise of Baxter’s Advanced Therapies
|
|
AstraZeneca:
Bending the Curve of CKD Medicine with
SGLT2i
|
|
Sanofi:
Application of Genetics in the Care of
Kidney Patients
|
|
Nipro Asia:
Super High Flux Dialyzer and Mortality in
Hemodialysis Patients
|
|
Bayer:
Non-Steroidal MRAs: Expanding the
Evidence-Base in CKD and T2D and Exploring
New Opportunities
|
|
Travere Therapeutics:
The Link Between Endothelin-1, Angiotensin
II, and Proteinuria in the Pathophysiology
of CKD
|
|
Otsuka:
The International Patient and Provider
Voice in IgA Nephropathy
|
|
Novartis:
Addressing the Unmet Needs in
Complement-Mediated Kidney Diseases
|
|
AstraZeneca:
Controversies in Hyperkalaemia Management
and Practical Approaches
|
|
Boehringer Ingelheim & Lilly
Alliance:
A Discussion with KDIGO: Advancing
Evidence-Based Care in Diabetes and CKD
|
|
|
Industry Symposia are open-access.
Available on-demand on the WCN platform
until May 31, 2022.
|
|
|